Dr. Ype P. De Jong, MD, PhD

Dr. De Jong practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. De Jong's NPI, 1205009958, was assigned on April 2, 2008. Dr. De Jong holds New York license 003045.

Dr. De Jong's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. De Jong's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. De Jong to 2 more clinical labs, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. De Jong practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. De Jong's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. De Jong is licensed in New York.

Dmand AI lists cirrhosis of the liver, colonoscopy, fatty liver, gastroenteritis, gastrointestinal bleeding, hepatitis c and upper GI endoscopy among the conditions Dr. De Jong treats.

CMS data shows 109 Medicare services from Dr. De Jong across 6 procedure codes in 2024, for 103 Medicare patients. Medicare paid $11,593 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 103 Medicare patients who saw Dr. De Jong in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. De Jong's median patient age at 61, with 47% women.

In 2024, Dr. De Jong wrote 108 Medicare Part D claims for 33 patients. 86% of them were for generic drugs. CMS names the drug for 57 of them, across 3 drugs with 11 or more claims each, at $12,723 in total drug cost. In 2023, CMS named 31 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. De Jong for performance year 2024, reported through an alternative payment model (APM). Dr. De Jong accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. De Jong as offering telehealth. CMS counts 26 procedures of colonoscopy by Dr. De Jong, more than 51% of the clinicians it reports for that procedure.

Dmand AI links 65 papers to Dr. De Jong, published from 2010 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Hepatocytes, Hepacivirus and Hepatitis B virus. Dr. De Jong has published most often in Mol Ther. Dr. De Jong's most frequent co-authors are Jing Xiao, MD, Gadi Lalazar, MD and Philip Coffino, MD.

CMS Open Payments shows 6 general payments to Dr. De Jong from 4 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 77% of the total. Pfizer Inc. paid the most, $4,000.

Dr. De Jong is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.